1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr.
2. Mottet N, Bellmunt J, Briers E, et al. European Association of Urology. Guidelines on prostate cancer. http://uroweb.org/guideline/prostate-cancer/.
3. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study;Beer;J Clin Oncol,2014
4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012
5. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study;Shore;Lancet Oncol,2016